By Marie Rosenthal, MS
Calling it a milestone, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted unanimously for universal use of nirsevimab (Beyfortus, AstraZeneca) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in very young infants.
“This is a milestone,” said ACIP committee member Sarah S. Long, MD, the chair of the ACIP’s Maternal/Pediatric RSV Work Group. “This is the very first antibody protection against